Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies

Paul M. Weinberger, Ziwei Yu, Diane Kowalski, John Joe, Phillip Manger, Amanda Psyrri, Clarence T. Sasaki

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Objective: To examine the expression of c-Met, c-Erb-b2 (HER2/neu), and epidermal growth factor (EGFR) in a cohort of 12 chordomas, based on the current and future availability of targeted molecular inhibitors. Design: Protein expression levels were analyzed by immunohistochemical analysis from archival tissue using multitumored tissue microarray and by Spearman rank correlation test. Setting: Tertiary care facility. Subjects: We assembled the cohort of 12 chordomas from patients treated at the Yale-New Haven Hospital from 1986 to 2003 and compared them with 51 other tumors from 17 assorted solid tissue tumor types along with 1 sample of healthy tissue from each site. Main Outcome Measure: The expression of c-Met, HER2/neu, and EGFR. Results: Most chordomas displayed strong expression of EGFR and c-Met, whereas a variable level of expression of HER2/neu was seen. In addition, we noted a strong correlation between EGFR and c-Met expression, especially for primary chordomas (P=.006). Conclusions: Chordomas, like many other solid-tissue tumors, express HER2/neu, EGFR, and the hepatocyte growth factor/scatter factor receptor c-Met. Most chordomas had strong expression of both the hepatocyte growth factor/scatter factor receptor and EGFR. Inhibitors to EGFR are already in clinical use for other solid-tissue tumors and represent a potentially viable experimental treatment option for refractory chordoma. Further studies are required to investigate these findings.

Original languageEnglish (US)
Pages (from-to)707-711
Number of pages5
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume131
Issue number8
DOIs
StatePublished - Aug 1 2005

Fingerprint

Chordoma
Epidermal Growth Factor Receptor
Epidermal Growth Factor
Neoplasms
Proto-Oncogene Proteins c-met
Hepatocyte Growth Factor
Tertiary Healthcare
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. / Weinberger, Paul M.; Yu, Ziwei; Kowalski, Diane; Joe, John; Manger, Phillip; Psyrri, Amanda; Sasaki, Clarence T.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 131, No. 8, 01.08.2005, p. 707-711.

Research output: Contribution to journalArticle

Weinberger, Paul M. ; Yu, Ziwei ; Kowalski, Diane ; Joe, John ; Manger, Phillip ; Psyrri, Amanda ; Sasaki, Clarence T. / Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. In: Archives of Otolaryngology - Head and Neck Surgery. 2005 ; Vol. 131, No. 8. pp. 707-711.
@article{787e6dcad16b415e8f1edaa0835d8c5c,
title = "Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies",
abstract = "Objective: To examine the expression of c-Met, c-Erb-b2 (HER2/neu), and epidermal growth factor (EGFR) in a cohort of 12 chordomas, based on the current and future availability of targeted molecular inhibitors. Design: Protein expression levels were analyzed by immunohistochemical analysis from archival tissue using multitumored tissue microarray and by Spearman rank correlation test. Setting: Tertiary care facility. Subjects: We assembled the cohort of 12 chordomas from patients treated at the Yale-New Haven Hospital from 1986 to 2003 and compared them with 51 other tumors from 17 assorted solid tissue tumor types along with 1 sample of healthy tissue from each site. Main Outcome Measure: The expression of c-Met, HER2/neu, and EGFR. Results: Most chordomas displayed strong expression of EGFR and c-Met, whereas a variable level of expression of HER2/neu was seen. In addition, we noted a strong correlation between EGFR and c-Met expression, especially for primary chordomas (P=.006). Conclusions: Chordomas, like many other solid-tissue tumors, express HER2/neu, EGFR, and the hepatocyte growth factor/scatter factor receptor c-Met. Most chordomas had strong expression of both the hepatocyte growth factor/scatter factor receptor and EGFR. Inhibitors to EGFR are already in clinical use for other solid-tissue tumors and represent a potentially viable experimental treatment option for refractory chordoma. Further studies are required to investigate these findings.",
author = "Weinberger, {Paul M.} and Ziwei Yu and Diane Kowalski and John Joe and Phillip Manger and Amanda Psyrri and Sasaki, {Clarence T.}",
year = "2005",
month = "8",
day = "1",
doi = "10.1001/archotol.131.8.707",
language = "English (US)",
volume = "131",
pages = "707--711",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies

AU - Weinberger, Paul M.

AU - Yu, Ziwei

AU - Kowalski, Diane

AU - Joe, John

AU - Manger, Phillip

AU - Psyrri, Amanda

AU - Sasaki, Clarence T.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Objective: To examine the expression of c-Met, c-Erb-b2 (HER2/neu), and epidermal growth factor (EGFR) in a cohort of 12 chordomas, based on the current and future availability of targeted molecular inhibitors. Design: Protein expression levels were analyzed by immunohistochemical analysis from archival tissue using multitumored tissue microarray and by Spearman rank correlation test. Setting: Tertiary care facility. Subjects: We assembled the cohort of 12 chordomas from patients treated at the Yale-New Haven Hospital from 1986 to 2003 and compared them with 51 other tumors from 17 assorted solid tissue tumor types along with 1 sample of healthy tissue from each site. Main Outcome Measure: The expression of c-Met, HER2/neu, and EGFR. Results: Most chordomas displayed strong expression of EGFR and c-Met, whereas a variable level of expression of HER2/neu was seen. In addition, we noted a strong correlation between EGFR and c-Met expression, especially for primary chordomas (P=.006). Conclusions: Chordomas, like many other solid-tissue tumors, express HER2/neu, EGFR, and the hepatocyte growth factor/scatter factor receptor c-Met. Most chordomas had strong expression of both the hepatocyte growth factor/scatter factor receptor and EGFR. Inhibitors to EGFR are already in clinical use for other solid-tissue tumors and represent a potentially viable experimental treatment option for refractory chordoma. Further studies are required to investigate these findings.

AB - Objective: To examine the expression of c-Met, c-Erb-b2 (HER2/neu), and epidermal growth factor (EGFR) in a cohort of 12 chordomas, based on the current and future availability of targeted molecular inhibitors. Design: Protein expression levels were analyzed by immunohistochemical analysis from archival tissue using multitumored tissue microarray and by Spearman rank correlation test. Setting: Tertiary care facility. Subjects: We assembled the cohort of 12 chordomas from patients treated at the Yale-New Haven Hospital from 1986 to 2003 and compared them with 51 other tumors from 17 assorted solid tissue tumor types along with 1 sample of healthy tissue from each site. Main Outcome Measure: The expression of c-Met, HER2/neu, and EGFR. Results: Most chordomas displayed strong expression of EGFR and c-Met, whereas a variable level of expression of HER2/neu was seen. In addition, we noted a strong correlation between EGFR and c-Met expression, especially for primary chordomas (P=.006). Conclusions: Chordomas, like many other solid-tissue tumors, express HER2/neu, EGFR, and the hepatocyte growth factor/scatter factor receptor c-Met. Most chordomas had strong expression of both the hepatocyte growth factor/scatter factor receptor and EGFR. Inhibitors to EGFR are already in clinical use for other solid-tissue tumors and represent a potentially viable experimental treatment option for refractory chordoma. Further studies are required to investigate these findings.

UR - http://www.scopus.com/inward/record.url?scp=23944515380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944515380&partnerID=8YFLogxK

U2 - 10.1001/archotol.131.8.707

DO - 10.1001/archotol.131.8.707

M3 - Article

C2 - 16103303

AN - SCOPUS:23944515380

VL - 131

SP - 707

EP - 711

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 8

ER -